Fuller L M, Hagemeister F B, North L B, McLaughlin P, Velasquez W S, Cabanillas F
University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston 77030.
Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):683-92. doi: 10.1016/0360-3016(88)90090-9.
Fifty-eight laparotomy-staged I and II patients with upper torso presentations of Hodgkin's disease and 8 patients with lymphangiogram-staged lower torso disease were treated with radiotherapy alone or with 2 cycles of MOPP and radiotherapy. Patients with upper torso disease with either no mediastinal or only small mediastinal disease without hilar involvement and with no "B" symptoms were treated with mantle radiotherapy alone. Patients with large mediastinal masses or hilar disease were treated with 2 cycles of MOPP followed by definitive mantle irradiation and low dose lung irradiation. Those for whom "B" symptoms were the only adverse prognostic feature received 2 cycles of MOPP and mantle radiotherapy. Patients with lower torso disease were treated with radiotherapy alone if the disease was limited to the pelvis. Those with more extensive disease received 2 cycles of MOPP prior to radiotherapy. The 4-year survival for all 66 patients was 97%. The corresponding disease-free and freedom from second relapse figures were 77% and 92%. Survival for the patients with unfavorable presentations who received 2 cycles of MOPP and radiotherapy was 100%. It was 92% for the group with favorable presentations who were treated with radiotherapy only.
58例剖腹术分期为I期和II期的上半身霍奇金病患者以及8例淋巴管造影分期为下半身疾病的患者接受了单纯放疗或2周期MOPP方案化疗加放疗。上半身疾病且无纵隔病变或仅有无肺门受累的小纵隔病变且无“B”症状的患者接受单纯斗篷野放疗。有大纵隔肿块或肺门病变的患者接受2周期MOPP方案化疗,随后进行根治性斗篷野照射和低剂量肺部照射。“B”症状是唯一不良预后特征的患者接受2周期MOPP方案化疗和斗篷野放疗。下半身疾病局限于骨盆的患者接受单纯放疗。病变范围更广的患者在放疗前接受2周期MOPP方案化疗。66例患者的4年生存率为97%。相应的无病生存率和无二次复发率分别为77%和92%。接受2周期MOPP方案化疗和放疗的预后不良患者的生存率为100%。仅接受放疗的预后良好患者组的生存率为92%。